Theranostics 2017; 7(11):2806-2821. doi:10.7150/thno.19081 This issue Cite

Research Paper

Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin

Lovro Kramer1, 2, Miha Renko1, Janja Završnik1, 2, Dušan Turk1, 3, Markus A. Seeger4, Olga Vasiljeva1, Markus G. Grütter5, Vito Turk1, Boris Turk1, 3✉

1. Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Ljubljana, Slovenia;
2. International Postgraduate School Jozef Stefan, Ljubljana, Slovenia;
3. Center of Excellence CIPKEBIP, Ljubljana, Slovenia;
4. Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland;
5. Department of Biochemistry, University of Zürich, Zürich, Switzerland.

Citation:
Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O, Grütter MG, Turk V, Turk B. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics 2017; 7(11):2806-2821. doi:10.7150/thno.19081. https://www.thno.org/v07p2806.htm
Other styles

File import instruction

Abstract

Graphic abstract

Cysteine cathepsins often contribute to cancer progression due to their overexpression in the tumour microenvironment and therefore present attractive targets for non-invasive diagnostic imaging. However, the development of highly selective and versatile small molecule probes for cathepsins has been challenging. Here, we targeted tumour-associated cathepsin B using designed ankyrin repeat proteins (DARPins). The selective DARPin 8h6 inhibited cathepsin B with picomolar affinity (Ki = 35 pM) by binding to a site with low structural conservation in cathepsins, as revealed by the X-ray structure of the complex. DARPin 8h6 blocked cathepsin B activity in tumours ex vivo and was successfully applied in in vivo optical imaging in two mouse breast cancer models, in which cathepsin B was bound to the cell membrane or secreted to the extracellular milieu by tumour and stromal cells. Our approach validates cathepsin B as a promising diagnostic and theranostic target in cancer and other inflammation-associated diseases.

Keywords: protease, cathepsin B, designed ankyrin repeat protein (DARPin), non-invasive diagnostic imaging, tumour microenvironment.


Citation styles

APA
Kramer, L., Renko, M., Završnik, J., Turk, D., Seeger, M.A., Vasiljeva, O., Grütter, M.G., Turk, V., Turk, B. (2017). Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics, 7(11), 2806-2821. https://doi.org/10.7150/thno.19081.

ACS
Kramer, L.; Renko, M.; Završnik, J.; Turk, D.; Seeger, M.A.; Vasiljeva, O.; Grütter, M.G.; Turk, V.; Turk, B. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics 2017, 7 (11), 2806-2821. DOI: 10.7150/thno.19081.

NLM
Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O, Grütter MG, Turk V, Turk B. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics 2017; 7(11):2806-2821. doi:10.7150/thno.19081. https://www.thno.org/v07p2806.htm

CSE
Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O, Grütter MG, Turk V, Turk B. 2017. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics. 7(11):2806-2821.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.